Le Lézard
Classified in: Covid-19 virus
Subjects: HSP, STP, AVO

Los Angeles Says: Too Much Alcohol on These Streets!


LOS ANGELES, July 7, 2021 /PRNewswire/ -- Members of California Alcohol Policy Alliance (CAPA) will hold an opposition rally at the Los Angeles district office of California State Assemblymember Jesse Gabriel (D-Encino), principal author of  AB 61 & coauthor SB 314. Both bills focus on expanding alcohol consumption on public property.

As all California communities struggle to recover from COVID, those most disproportionately socio-economically impacted are black, brown and low-income. For them there is no relief in Gabriel's bills which prioritize business economic recovery. He is completely disregarding the unintended consequences of his misguided efforts: high costs of implementation, lack of infrastructure, and loss of overriding local control of cities to implement safe street and sidewalk initiatives for residents and business alike.

This is a social justice issue for low-income and communities of color, pedestrians and drivers already severely compromised by heavy policing, lack of resources, and limited access to walkable and family friendly city streets. Promoting the need for non-union low paying jobs for communities of color as a means to justify alcohol deregulation co-opts social justice and equity to advance corporate profits. The real question is: who is funding these initiatives because it is not the labor unions and it is not the community.

In 2020, Assemblymember Gabriel received $5,700 from the Beer, Wine and Liquor sector ? $4,700 from Anheuser-Busch (a multinational corporation headquartered in Belgium) and $1,000 from Wine Institute a corporate alcohol funded lobbyist organization. Gabriel's bills will effectively privatize public spaces and compromise pedestrian right-of-way safety in the City of Los Angeles.

What:   Opposition Rally & Call to Action
When:  Thursday July 8, 2020, 11 a.m. to noon
Where: 20750 Ventura Blvd. Suite 101, Woodland Hills, CA 91364
Who:

Why:   

With this event, CAPA is launching a public CALL to ACTION to demand that Assemblymember Gabriel, the Legislature, and the Governor acknowledge that excessive alcohol use is No. 3 on the list of preventable causes of death in California and stop any bills seeking to extend or expand COVID-19 regulatory rollbacks for economic relief.

Take Action here: : https://bit.ly/3oFz1uo or text PUBLICHEALTH to 313131 to tell legislators and the Governor to choose PUBLIC HEALTH over industry profits and STOP AB 61 AND SB 314.

The California Alcohol Policy Alliance (CAPA) unites diverse organizations and communities in California to protect health and safety, and prevent alcohol-related harm through statewide action.

CAPA Member Organizations

For more information go to: https://alcoholpolicyalliance.org/ or https://alcoholjustice.org/

CONTACT:

Mayra Jimenez 323 683-4687 


Raul Verdugo 310 689-9401


Michael Scippa 415 548-0492

 

SOURCE California Alcohol Policy Alliance


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: